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Computational insights into the inhibition of
β-haematin crystallization by antimalarial drugs†
Anjana M. D. S. Delpe Acharige,a,b Mark P. C. Brennan,a Kate Lauder, a,c
Fiona McMahon,a Adesola O. Odebunmia and Marcus C. Durrant *‡a
During the red blood cell phase of their life cycle, malaria parasites digest their host’s haemoglobin, with
concomitant release of potentially toxic iron(III) protoporphyrin IX (FePPIX). The parasites’ strategy for detox-
iﬁcation of FePPIX involves its crystallization to haemozoin, such that the build-up of free haem in solution
is avoided. Antimalarial drugs of both historical importance and current clinical use are known to be capable
of disrupting the growth of crystals of β-haematin, which is the synthetic equivalent of haemozoin. Hence,
the disruption of haemozoin crystal growth is implicated as a possible mode of action of such drugs.
However, the details of β-haematin crystal poisoning at the molecular level have yet to be fully elucidated.
In this study, we have used a combination of density functional theory (DFT) and molecular modelling to
examine the possible modes of action of ten diﬀerent antimalarial drugs, including quinine-type aliphatic
alcohols, amodiaquine-type phenols, and chloroquine-type aliphatic diamines. The DFT calculations indi-
cate that each of the drugs can form at least one molecular complex with FePPIX. These complexes have
1 : 1 or 2 : 1 FePPIX : drug stoichiometries and all of them incorporate Fe–O bonds, formed either by direct
coordination of a zwitterionic form of the drug, or by deprotonation of water. Most of the drugs can form
more than one such complex. We have used the DFT model structures to explore the possible formation of
a monolayer of each drug–haem complex on four of the β-haematin crystal faces. In all cases, the drug
complexes can form a monolayer on the fast-growing {001} and {011} faces, but not on the slower growing
{010} and {100} faces. Additional modelling of the chloroquine and quinidine complexes shows that individ-
ual molecules of these species can also obstruct the growth of new layers on other crystal faces. The impli-
cations of these observations for antimalarial drug development are discussed.
Introduction
Malaria is a mosquito-borne disease resulting from infection
with various species of Plasmodium genus parasites, of which
P. falciparum and P. vivax pose the greatest risk to public
health. Although the World Health Organization has been able
to document significant inroads against this disease in pre-
vious years, their latest report notes a troubling slowdown in
progress.1 Moreover the eradication of malaria remains a
distant goal, such that over 3 billion people are at risk world-
wide, with 445 000 deaths in 2016 alone.1 The global fight
against malaria pursues a broad strategy, of which antimalarial
drugs remain a key component. However, several previously
highly eﬃcacious and cost-eﬀective antimalarials have been
rendered less eﬀective by the emergence of resistant
Plasmodium strains, and it is surely only a matter of time
before current front-line drugs go the same way. Therefore, the
development of novel antimalarials remains an important
objective in medicinal chemistry.
Although the precise modes of action of many antimalarial
drugs are currently unknown, it is clear that one of the
primary targets is not a protein or DNA, but rather the haem
that is released by the Plasmodium parasite as it digests
haemoglobin within the host’s red blood cells.2–4 This free
haem is in the form of iron(III) protoporphyrin IX (FePPIX,§
Scheme 1). In untreated patients, the parasite is able to detox-
†Electronic supplementary information (ESI) available: Atomic coordinates,
energies and electronic spins at Fe for all DFT models; pictures of complexes not
given in Fig. 1 and 6; pictures of all surface coverage models; shared surface area
data used to construct Fig. 2 and 5; comparison of free drug surface areas versus
β-haematin {001} face surface coverage. See DOI: 10.1039/c8dt03369b
‡Retired.
aFaculty of Health and Life Sciences, Northumbria University, Ellison Building,
Newcastle-upon-Tyne NE2 8ST, UK. E-mail: marcus.durrant@gmail.com
bDepartment of Chemistry, Kansas State University, Manhattan, Kansas, 66506, USA
cSchool of Cancer and Pharmaceutical Sciences, King’s College London,
150 Stamford Street, London SE1 9NH, UK
§Throughout this paper, FePPIX is used to indicate the generic form of iron(III)
protoporphyrin IX. Specific forms of FePPIX in which one or both propionate
groups are in their neutral, protonated form are designated as FePPIXH and
FePPIXH2 respectively.
15364 | Dalton Trans., 2018, 47, 15364–15381 This journal is © The Royal Society of Chemistry 2018
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
9 
O
ct
ob
er
 2
01
8.
 D
ow
nl
oa
de
d 
on
 2
/1
8/
20
19
 1
1:
57
:5
9 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e. View Article Online
View Journal  | View Issue
ify this molecule by a type of biomineralization, such that at
least 95% of the FePPIX is locked away in its iron(III) form as
poorly soluble haemozoin crystals.5 A number of antimalarial
drugs are thought to act by disrupting the process of haemo-
zoin crystallization. This can be accomplished by poisoning
the growing crystal surfaces, perhaps by formation of a
surface monolayer that is no longer recognized by incoming
FePPIX molecules.2,3 It has recently been shown that crystals
of β-haematin, which is accepted as the synthetic analogue of
haemozoin, can adsorb chloroquine from solution, and that
the abilities of several inhibitors to retard the growth of
β-haematin in vitro are correlated with the strength of their
adsorption on the crystal surfaces.6 The overall picture has
been further refined by time-resolved atomic force
microscopy (AFM) studies, which were used to characterize
the in vitro growth of β-haematin crystals in both the absence
and presence of antimalarial drugs.6–8 These experiments
indicated that the crystallization of FePPIX proceeds by a
classical mechanism in which new 2D crystal layers are
nucleated on existing crystal surfaces. In this scenario, rela-
tively low concentrations of the drugs can poison crystal
growth by a variety of molecular scale interactions at critical
points of the developing 2D surface layers. Further studies
revealed that chloroquine (CQ) binds preferentially to the
{001} crystal surfaces, whereas amodiaquine (AQ) binds non-
preferentially to both the {001} and {010} surfaces.9 Both CQ
and AQ are able to form 2 : 1 FePPIX : drug complexes,8 but
the formation of such complexes is not necessarily correlated
with the ability to inhibit β-haematin crystal growth. More
generally, published experimental studies have not yet been
able to resolve the question of whether free drug molecules
or molecular drug–haem complexes are responsible for
crystal poisoning.
The powder X-ray crystal structure of β-haematin has been
reported by Pagola et al.2 The structure is assembled from
(FePPIXH)2 dimers, in which the five-coordinate iron(III)
centres are reciprocally bonded to propionate oxygens from
their partners, with an Fe–O bond length of 1.886(2) Å. The
second propionate group of each monomer is in its neutral,
protonated form, and participates in a cyclic hydrogen bond
with the neighbouring dimer (Scheme 1, 1). Given the enantio-
facial symmetry of the FePPIX monomer, arising from the
diﬀerent positions of its two vinyl groups, the (FePPIXH)2
dimer can in principle exist as four diﬀerent stereoisomers;
further examination of the β-haematin crystal structure led
Straasø et al. to conclude that 86% of their sample was com-
posed of the cd1ˉ1 isomer as described by Pagola et al., whilst
the remainder consisted of the cd1ˉ2 isomer; both phases were
also thought to be occluded with the two chiral cd2(+) and cd2
(−) enantiomers.10 Density functional theory (DFT) calcu-
lations by Marom et al.11 on the isolated dimers indicated that
the cd1ˉ1 dimer has the lowest energy in vacuo, but that the cd1ˉ2
and cd(2) dimers are only marginally higher in energy, by ca.
2 kcal mol−1; whilst in the crystalline phase, the preference for
the cd1ˉ1 dimer is enhanced by ca. 9–16 kcal mol
−1
. These
results are also consistent with a model in which the major
and minor crystal phases are composed of the cd1ˉ1 and cd1ˉ2
dimers respectively, plus occluded cd(2) dimers. In terms of
crystal growth, it is generally the case that the size of a given
crystal face is inversely proportional to its rate of propagation.
On this basis, a theoretical study12 identified the {100} and
{010} faces as being the most developed, with smaller {011}
and {001} faces; the latter two faces, as the fastest growing,
would be the primary target for drugs that inhibit crystal
growth by a face coating mechanism. Scanning electron
microscopy showed changes in morphology of bulk
β-haematin crystals grown in the presence of various anti-
malarials, consistent with inhibition of the (001), (01ˉ1ˉ) and
possibly the {010} faces.8
Drugs that are thought to poison β-haematin crystal growth
by surface adsorption, as shown in Scheme 2, can be classified
according to their functional groups. All these drugs contain a
secondary or tertiary amine, plus a planar aromatic system of
10 or 14 π-electrons. In addition, some drugs incorporate a sec-
ondary aliphatic alcohol; this group includes quinine (QN),
quinidine (QD), mefloquine (MQ), halofantrine (HN) and
lumefantrine (LM). A second group consists of phenols, and
includes AQ and tebuquine (TQ). Finally, some drugs lack any
–OH functionality; these include CQ, mepacrine (MP), and
piperaquine (PQ). All ten of these drugs have been shown to
inhibit the growth of β-haematin crystals in vitro.13–15
Furthermore, representatives of all three groups, namely QN,
MQ, LM, AQ and CQ, have been shown to cause a decrease in
haemozoin and increase in free haem in P. falciparum para-
sites in vivo.4 The naturally occurring Cinchona alkaloids QN
and QD are both specific stereoisomers, whilst the synthetic
Scheme 1 Forms of iron(III) protoporphyrin IX featured in this study. Dimer (1) is found in crystalline β-haematin, whilst (2) is the π–π dimer encoun-
tered in solution.
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drugs MQ, HN, LM, CQ and MP, which all have at least one
stereocentre, are used clinically as racemic mixtures.
Important circumstantial evidence for the possible mode of
action of the alcohol-containing drugs has been provided in
the form of the X-ray crystal structures of 1 : 1 FePPIXH : drug
complexes with QN and QD,16 HN17 and, most recently, MQ.18
These structures all show several common features. In each
case the iron(III) centre is five-coordinate, being bound to the
deprotonated alcohol group of the drug by an alkoxide bond.
The amine nitrogen of the drug is protonated and forms a
hydrogen bond with the deprotonated propionate group of
FePPIXH. The exact details of the amine-propionate hydrogen
bonds vary; for QN, QD and MQ they are intramolecular,
whilst for HN they are intermolecular. In each case, the aro-
matic moiety of the drug shows a π–π stacking interaction with
the porphyrin ring. Finally, the second propionic acid group of
FePPIXH retains its proton, such that the iron(III) complex is
neutral overall. In contrast to this wealth of structural data,
and despite much eﬀort, no X-ray crystal structure of a mole-
cular complex of CQ with FePPIX has yet been published.
Spectroscopic techniques show that drugs such as CQ do inter-
act with FePPIX in solution,19 although the exact nature of the
interaction has remained elusive. Recently, Kuter et al. have
characterized the complex formed between FePPIX and CQ in
aqueous solution by means of a combined approach involving
EXAFS spectroscopy and molecular dynamics simulations.20 A
2 : 1 ratio of Fe(III) : CQ in aqueous solution was established,
leading to a model of stoichiometry [(FePPIXH)2(μ-O)(CQH2)],
as shown in Scheme 3, generic complex C. This complex was
characterized by EXAFS in terms of an Fe–O bond length of
1.87 Å, which is unusually long for an Fe(III)–O–Fe(III) dimer,
and an asymmetric ν(Fe–O–Fe) stretch at 744 cm−1 in the infra-
red. These indications of relatively weak Fe–O bonding were
attributed to a hydrogen bond between the μ-oxo atom and the
protonated quinoline nitrogen of the CQH2
2+ moiety. The pro-
tonated quinoline ring is intercalated between the two haem
rings, such that π–π stacking interactions are another impor-
tant feature of this complex.
Studies of the speciation of FePPIX in aqueous solution
have been complicated by its tendency to adsorb onto glass
and plastic surfaces. Using carefully prepared apparatus, de
Villiers et al. were able to minimize this problem,21 allowing
them to identify an equilibrium between the monomer and a
π–π stacked (FePPIX)2 dimer (Scheme 1, 2) as the dominant
species in aqueous solution. In the π–π dimer, the iron(III)
atoms are five-coordinate, the axial ligand being either H2O or
OH−. We have previously found from DFT calculations that
whereas hydroxide is one of the most strongly bound ligands
for Fe(III)PPIX, water is among the weakest, such that neutral
water ligands should undergo rapid exchange.22 The addition
of 10% pyridine (Py) to an alkaline solution of FePPIX is
suﬃcient to induce formation of a μ-oxo [(FePPIX)2(μ-O)(PyH)]
dimer,21 analogous to the CQ complex discussed above.
However, crystallization of β-haematin requires assembly of
Scheme 2 Antimalarial drugs featured in this study.
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the propionate-bridged (FePPIXH)2 dimer 1, and this process
does not occur spontaneously from aqueous solutions of
FePPIX under normal physiological conditions. Therefore, the
malaria parasite facilitates the growth of haemozoin in its
digestive vacuole (DV) by a combination of low pH (ca. 4.8) and
the presence of lipids; in particular, a water–lipid interface
appears to be required for crystal growth.7,23 X-ray tomography
experiments led Kapishnikov et al. to conclude that haemozoin
nucleation occurs at the inner membrane of the DV, with sub-
sequent crystal growth in the aqueous phase.24 A somewhat
diﬀerent view was taken by Kuter et al., who showed that gly-
cerolipids are the key players in haemozoin nucleation.25
Using computational methods, they extended their studies to
develop a molecular scale model of crystal growth in which the
lipid interior is the site of conversion of the π–π (FePPIX)2
dimer 2 into the propionate-bridged dimer 1, such that crystal
growth is propagated at the lipid–water interface. Regardless of
the exact mechanisms of haemozoin nucleation and growth,
the acidic, lipid-rich conditions of the DV are conducive to
attainment of the required FePPIXH protonation state, in
which only one of the haem propionates is protonated (we
have previously calculated pKa values of 4.3 and 5.5 for the two
propionates,22 compared to the pH of ca. 4.8 for the DV).
Moreover, these conditions encourage protonation of strongly
bound OH− ligands to give weakly bound H2O ligands; they
also enhance the competitiveness of propionate over water for
axial binding to the Fe(III) centre;22,25 and attenuate the
strength of π–π stacking interactions.26 This is also consistent
with in vitro crystal growth experiments under biomimetic con-
ditions,27 which showed that large β-haematin crystals can be
obtained by nucleation at an octanol-citric buﬀer interface, fol-
lowed by seeding into FePPIX-saturated octanol in contact with
citric buﬀer for further growth. Attempts to grow crystals in
either purely aqueous solutions or in anhydrous octanol gave
much poorer results.
It is conceivable that the antimalarials in Scheme 2 poison
the growth of β-haematin crystals by direct and possibly non-
specific interactions with the crystal surfaces. However, the
experimental evidence discussed above, showing that several
drugs form molecular complexes with FePPIX, raises the ques-
tion of whether such complexes, rather than the free drug
molecules, might be responsible for inhibition of β-haematin
growth. With respect to CQ, we have previously used DFT cal-
culations to postulate a theoretical 1 : 1 complex between CQ
and FePPIX, in which the drug stabilizes the coordination of a
hydroxide ligand, generated from water, at the iron(III) centre
(Scheme 3, generic complex B).28 The recruitment of water to
form a hydroxide ligand with transfer of the proton to the ter-
tiary amine of CQ would then be analogous to the action of
the alcohol-containing drugs, which act as alkoxide ligands to
FePPIX with internal proton transfer to the amine. Meanwhile,
as discussed above, experimental studies have confirmed that
Scheme 3 Generic complexes of FePPIX with antimalarial drugs. All structures are shown as neutral overall; formal atomic charges are omitted for
simplicity. In the Venn diagram, the letters A, B and C pertain to the generic complexes in the main scheme.
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CQ can indeed recruit a water molecule to support an Fe–O
bonded complex with FePPIX, however the observed
FePPIX : drug stoichiometry is 2 : 1 rather than 1 : 1 (Scheme 3,
complex C).20
With these observations in mind, we set out to investigate
by theoretical methods whether known and/or putative
FePPIX–drug complexes could indeed be responsible for the
disruption of β-haematin crystallization. We were particularly
interested in exploration of the hypothesis that complexes of
FePPIX with antimalarial drugs might poison the growth of
β-haematin by forming a monolayer on the fastest growing
crystal surfaces. To this end, we have carried out DFT calcu-
lations to obtain structures and formation energies for mole-
cular complexes of the ten diﬀerent β-haematin inhibiting
drugs shown in Scheme 2 with FePPIX. We have also used
rigid body modelling and molecular mechanics (MM) calcu-
lations to investigate the formation of monolayers of these
complexes on the primary crystal surfaces of β-haematin. The
results of our studies are presented in this paper.
Results and discussion
Methodology and overview
In our previous work,22 we used the experimental binding
energies26 of a series of N-donor ligands with FePPIX to evalu-
ate the accuracy of three diﬀerent DFT procedures employing
the B3LYP and OPBE functionals in combination with the
LanL2DZ and 6-311+G(d,p) basis sets. These ligands are all
characterized as coordinating to the iron(III) centre of FePPIX,
rather than interacting by π–π stacking. The best results were
obtained by geometry optimization and zero-point energy
(ZPE) calculations at the B3LYP/LanL2DZ level, followed by
single point calculations with B3LYP/6-311+G(d,p) plus SMD
implicit solvent corrections for n-octanol or water as required
(method 3). This gave a correlation coeﬃcient R2 of 0.865
between the calculated ΔE values and experimental ΔG values.
At the outset of the present work, two additional functionals
were tested, namely B97D and wB97XD; these were developed
to incorporate dispersion and are reported to give good per-
formance in geometry optimizations of transition metal com-
plexes.29 First, the geometries previously obtained at the
B3LYP/LanL2DZ level of theory were used for single point cal-
culations in water, using the SMD implicit solvent model and
either B97D/6-311+G(d,p) (method 4) or wB97XD/6-311+G(d,p)
(method 5). Next, the geometries were recalculated at the
B97D/LanL2DZ level and used for single point calculations in
water using SMD plus wB97XD/6-311+G(d,p) (method 6). ZPE
corrections were included in all cases. The results are summar-
ized in Table 1, along with those previously obtained using
method 3. In terms of the correlation with experimental data,
methods 4–6 were all found to be somewhat inferior to
method 3. Also, as found previously, the values of ΔE obtained
with method 3 were closest to the experimental ΔG values.
This agreement should not, of course, be taken at face value,
since entropy has not been taken into account; although the
gas phase entropies of the individual molecules are available
from our calculations, we are unable to estimate the contri-
butions from solvent. Nevertheless, based on these results, we
have employed method 3 throughout this study also. DFT cal-
culations on the very large [(FePPIXH)2(μ-O)(drugH2)] com-
plexes investigated in this study presented some additional
complications. The final single point calculations with the 6-
311+G(d,p) basis set proved to be intractable for all the drugs
except CQ. Exploratory calculations showed that the largest all-
electron basis set that could be used successfully on these
complexes was 6-31G, but evaluation of this method by the
above procedure gave an R2 value of 0.741. We therefore
reverted to our previously described method 1,22 which uses
B3LYP/LanL2DZ for geometry optimization, ZPE calculation,
and SMD solvent steps, and gave an R2 value for ΔE versus ΔG
of 0.840. Meanwhile, using a fragment-based approach to set
up the two Fe centres in the dinuclear complexes as antiferro-
magnetically coupled (overall S = 0) generally gave incorrect,
low spins on each metal. To achieve the correct atomic spins,
it was necessary to run a sequence of spin-perturbed calcu-
lations (S = 1/2, 3/2, 1/2, 0, using guess = read and varying the
overall molecular charge as required), until the magnitude of
the spin on each iron matched those seen in the corres-
ponding mononuclear complexes. Final spin values are given
in the ESI.†
Although method 3 does not incorporate dispersion and
hence π–π stacking interactions, the strengths of such associ-
ations are quite well known from experimental studies. For
example, measurements on the interactions of simple aro-
matic molecules with substituted porphyrins in aqueous solu-
Table 1 Comparison of experimentally obtained free energies (ΔG) and calculated bond energies (ΔE) for coordination of N-donor ligands in water
Species ΔGa/kcal mol−1
Method 3b Method 4 Method 5 Method 6
ΔE/kcal mol−1 ΔE/kcal mol−1 ΔE/kcal mol−1 ΔE/kcal mol−1
Pyridine −1.05 −3.48 −16.6 −15.5 −15.0
4-Methyl pyridine −1.83 −4.21 −17.4 −16.3 −15.8
Imidazole −3.03 −5.75 −16.9 −16.6 −16.2
Morpholine −4.88 −5.70 −22.4 −20.2 −20.3
4-Dimethyl aminopyridine −5.44 −6.70 −20.3 −18.9 −18.3
n-Butylamine −6.15 −8.56 −21.0 −19.2 −19.0
Correlation coeﬃcient, R2 0.865 0.745 0.842 0.790
a Values calculated from the data given in ref. 26. b Values taken from ref. 22.
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tion showed an excellent linear correlation between the
number of π-electrons in the aromatic ring system and the dis-
persion contribution to the free energy, ΔGdisp, equivalent to
ca. 1.7, 3.8 and 4.4 kcal mol−1 for aromatic systems of 6, 10
and 14 electrons of respectively.30 The incorporation of hetero-
atoms made very little diﬀerence and the value for quinoline,
of particular relevance to this study, was 3.9 kcal mol−1. These
dispersion interactions will be somewhat attenuated in sol-
vents of higher polarizability than water,31 as found in the
malaria parasite’s lipid-rich DV.
In attempting to calculate the interaction energies of anti-
malarial drugs with FePPIX, proper account must be taken of
the conformational flexibilities of these molecules, particularly
the free drugs. Therefore, at least 30 diﬀerent input geometries
of each free drug molecule were used for the DFT calculations,
in order to locate the global minimum with reasonable cer-
tainty. Input geometries were generated by torsional searching
and/or molecular dynamics (further details are given under
Computational methods). It should be noted that the
minimum energy conformations found using implicit solvent
n-octanol and water models were not always the same. X-ray
crystal structures are available for several of the free drugs;
these were also used as inputs for DFT calculations, and are
compared with the calculated global minima in the following
sections. For the FePPIX–drug complexes, fewer conformations
were examined, due both to the reduced conformational flexi-
bility of these molecules and the much greater expense of the
calculations. Hence, any bias in our data is likely to be in
favour of the free drug molecules, leading to underestimation
of their FePPIX interaction energies. In the crystal structure of
β-haematin, individual dimers are uncharged such that the
crystal is a non-ionic lattice. Therefore, we have focussed our
attention on neutral FePPIX–drug complexes, since the accre-
tion of a layer of like-charged ions on a non-ionic crystal
surface seems less likely on electrostatic grounds.
As an aid to analysis of the various FePPIX–drug complexes
modelled in this study, Scheme 3 sets out the various possibili-
ties that have been considered in this work. Generic complex A
has a 1 : 1 FePPIXH : drug stoichiometry, and incorporates an
alkoxide Fe–O bond, with the drug in its zwitterionic form.
This possibility has been demonstrated experimentally by the
X-ray crystal structures of FePPIX complexes with QN, QD, MQ,
and HN.16–18 Complex B is an analogous 1 : 1 complex, in
which the Fe–O bond is supplied by hydroxide; we have pre-
viously postulated such a complex for CQ,28 although there is
no experimental evidence for this possibility at present.
Finally, complex C has a 2 : 1 FePPIX : drug stoichiometry and
includes a bridging oxo ligand; this type of structure has been
demonstrated in solution for CQ.20 For all ten drugs in this
study, DFT calculations on each of the relevant possibilities, A,
B, and C, have been carried out.
The ability of each FePPIX–drug complex to coat the {001},
{010}, {100} and {011} crystal faces of β-haematin was initially
investigated by rigid body modelling; Fig. S1 in the ESI† illus-
trates the steps involved in these calculations. First, the
required FePPIX–drug complex was placed within the
β-haematin crystal unit cell as reported by Pagola et al.,2 by
overlaying selected haem atoms of the complex with the equi-
valent atoms in one half of the native (FePPIXH)2 dimer. The
original (FePPIXH)2 dimer was then deleted to leave the
FePPIX–drug complex within the β-haematin unit cell. For all
ten drugs, some common features emerged at this point.
Thus, it proved possible to stack each of the FePPIX–drug unit
cells along their a and b axes, but stacking along the c axis
invariably led to severe steric clashes. Consequently, we found
that each of the complexes can form a monolayer on the {001}
and {011} β-haematin crystal faces, but not the {100} or {010}
faces. We note that the {010} and {100} faces are thought to
grow more slowly than the {001} and {011} faces;12 hence, all
the drug complexes considered in this work are predicted to
be selective in poisoning growth of the fastest growing crystal
faces. This does not exclude the possibility that single mole-
cules of the drug complexes could also interact with islands or
steps on the growing {100} or {010} faces; this has been investi-
gated for QD and CQ (see below). For the {001} and {011}
crystal faces, unit cells containing the FePPIX–drug complex
were assembled into a monolayer of (5 × 5 × 1) cells, which was
then docked onto a (5 × 5 × 2) unit cell model of the appropri-
ate β-haematin crystal face. The {100}, {001} and {011} faces of
β-haematin all include one half of the propionate hydrogen
bonded dimer which provides the only hydrogen bonding
interaction between unit cell layers. Hence, in docking the
FePPIX–drug layers onto the native structure, care was taken to
orientate the two models such that the propionate groups
matched up to form a new layer of hydrogen bonds.
Completed (5 × 5 × 3) models were then subjected to geometry
optimization as detailed below under Computational methods.
This required extension of the CHARMm force field to include
parameters for the haem group; although we employed ad hoc
values that were not rigorously developed, they proved
suﬃcient for our purposes, since the only major eﬀect of geo-
metry optimization was to resolve close contacts within the
initial models. Also, geometry optimizations of a native
β-haematin crystallite and the individual FePPIX–drug com-
plexes using our parameters gave good results when compared
to the X-ray crystal structure and the DFT geometries, respect-
ively. The optimized (5 × 5 × 3) models were analysed in terms
of overlapping surface area, which gives an indication of the
extent to which a monolayer of the drug complex covers the
surface of the crystal. This has been done in two ways; first, by
measuring the shared surface area (SSA) of the central drug
complex molecule in each model, subsequently referred to as
the plug SSA; and second, by measuring the shared surface
area of a single drug complex molecule placed on the centre of
a (5 × 5 × 2) haematin model (obtained by editing the (5 × 5 ×
3) model, and referred to as the single SSA; see Fig. S1 in the
ESI†). Further details are given in the Computational methods
section.
Mefloquine, halofantrine and lumefantrine
We commence our analysis of individual drugs with the sim-
plest case, which is provided by MQ, HN and LM. These syn-
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thetic antimalarials are all employed as mixtures of the two
possible stereoisomers at the alcohol function. HN and LM
lack any quinoline-type nitrogen, hence they cannot stabilize a
dinuclear [(FePPIXH)2(μ-O)] core complex (see below).
Although MQ includes a quinoline ring, it is easy to show by
molecular modelling that its two –CF3 substituents provide
suﬃcient steric hindrance to prevent the protonated quinoline
group from hydrogen bonding with the central oxygen of
[(FePPIXH)2(μ-O)]. Several X-ray crystal structures of free MQ
are available;32 these all show intermolecular OH⋯N hydrogen
bonds, together with intramolecular NH⋯O hydrogen bonds.
Our DFT calculations indicated slightly diﬀerent global
minima in n-octanol and water; the former showed an intra-
molecular OH⋯N hydrogen bond, whilst the latter showed an
NH⋯O hydrogen bond as observed in the crystal structures.
The diﬀerences in energy between the two geometries were
<0.4 kcal mol−1 in both solvents (see the ESI†). Using similar
DFT methodology, Fielding et al. also identified the NH⋯O
hydrogen bonded structure as the lowest energy conformation
in water,33 whilst Dassonville-Klimpt et al. concluded that the
choice of OH⋯N or NH⋯O intramolecular hydrogen bonding
depends on the enantiomer.32
The X-ray crystal structures of mononuclear alkoxide com-
plexes of FePPIXH with HN17 and MQ18 have been reported.
We have previously modelled the FePPIX–HN complex by DFT,
and found that the intermolecular hydrogen bond to propio-
nate observed in the crystal structure can be replaced by an
intramolecular equivalent in the isolated complex.28 In the
present work, we have extended our studies to the analogous
complexes of MQ and LM. The structures of all three DFT
model complexes are shown in Fig. 1. The crystal structure of
the FePPIXH–MQ complex shows a cyclic intramolecular
hydrogen bonding network involving both H atoms of the pro-
tonated piperidinium nitrogen, plus both the propionate and
propionic acid groups of FePPIXH;18 in our model, we have
simplified this such that the propionic acid group is not
involved in hydrogen bonding, and is therefore available for
docking to the haematin crystal surface. In other respects, our
model is in good agreement with the crystal structure.
The calculated energies of complex formation, using
method 3, are given in Table 2. We have previously28 examined
the energy profiles for the formation of such complexes in
terms of two hypothetical reaction steps, namely the formation
of the drug zwitterion (Scheme 3, step A1) followed by the reac-
tion of the latter with FePPIX (step A2). The results of these cal-
culations are also given in Table 2. The cost of zwitterion for-
mation is always more than oﬀset by the benefit of complexa-
tion, such that MQ, HN and LM are all predicted to form
stable complexes with FePPIX, in both n-octanol and water. As
discussed above, these complexes will be further stabilized by
π–π stacking between their aromatic rings and the haem,
which is not included in our calculations.
For all three of these zwitterionic complex models, the
neutral propionic acid group is not involved in intramolecular
hydrogen bonding, and is consequently available to form the
intermolecular propionic acid hydrogen bond seen in the
crystal structure of β-haematin. We have therefore investigated
the ability of these FePPIX–drug complexes to form mono-
layers on the most important crystal surfaces of β-haematin, as
described in the Methodology section. The SSA’s for the single
and plug models are shown graphically in Fig. 2. This plot
shows that all the mononuclear drug complexes give broadly
similar SSA’s. Although the single SSA values for single drug
complex molecules placed on the β-haematin faces are gener-
ally similar to those for the native (FePPIXH)2 dimer placed on
the {100} and {010} faces of the native crystal (horizontal axis),
the plug SSA’s (vertical axis) are appreciably smaller. In par-
ticular, the deep corrugations in the {001} faces remain largely
unoccupied by these mononuclear FePPIXH–drug complexes.
The surface coverage models for the HN complex, as represen-
tative of this class of drug, on the (001) and (011) crystal faces
are illustrated in Fig. 3 (drug-surface combinations not shown
in Fig. 3 are given in the ESI†). Apart from considerations of
van der Waals surface contact areas, the drug complex mono-
layers on both the {001} and {011} faces can participate in
cyclic propionate hydrogen bonding to dock with the
β-haematin surface, as seen for the native (FePPIXH)2 dimer.
Hence, the results of this theoretical study lend support to the
hypothesis that the crystallographically observed HN and MQ
complexes of FePPIXH, and the analogous complex of LM, are
all able to poison the growth of β-haematin by forming mono-
layers on the fast-growing {001} and {011} crystal faces. It
should be noted that since the opposite crystal faces of
β-haematin are mirror images, the complexes modelled here
will only complement one of each pair of crystal faces.
However, since these drugs are all used as racemic mixtures,
each of the resulting pairs of complexes will complement one
or other of the crystal face pairs.
Recently, Fielding et al. have concluded from DFT calcu-
lations that MQ could stabilize a hydroxy complex of FePPIX,
formulated as [FePPIXH2(OH)(MQH)]
+, perhaps as an inter-
mediate on the path to the experimentally characterized alk-
oxide complex.33 Apart from the overall positive charge, this
complex is analogous to the neutral 1 : 1 complex of CQ that
we postulated previously,28 and the hydroxy complexes of
several other drugs as discussed below.
Quinine and quinidine
The alkaloids QN and QD are diastereomers; X-ray crystal
structures of both the free drugs34,35 and their 1 : 1 complexes
with FePPIX16 are available. Our calculations on free QN indi-
cated slightly diﬀerent minimum energy structures in
n-octanol and water, associated with rotations about the two
C–C bonds adjacent to the hydroxy group; the diﬀerence in
energy between the two conformers is ca. 0.5 kcal mol−1 in
both solvents (section 17 of the ESI† gives values of these
torsion angles for the experimental and calculated structures
of QN and QD). The calculated minimum in n-octanol is in
excellent agreement with the X-ray crystal structure of QN.34
For QD, a single conformer was identified as the global
minimum in both solvents. This diﬀers from the X-ray crystal
structure of QD,35 both in the torsion angles of the C–C bonds
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adjacent to the hydroxy group, and in the disposition of the
MeO− group, which is flipped by 180° between the experi-
mental and calculated structures. In terms of these three
torsion angles, the calculated minimum for QD is very similar
to that obtained for QN in water. DFT calculations on the X-ray
geometry of QD (including geometry optimization) indicated
that it is 1.2 and 1.6 kcal mol−1 higher in energy than our
minimum, in n-octanol and water respectively. It is worth
noting that since the crystal structures of both drugs show
intermolecular hydrogen bonds, the crystal packing energies
are probably greater than the small energy diﬀerences found
in our calculations.
The crystal structures of the complexes of QN and QD with
FePPIX show that in both cases, the drug has again adopted a
zwitterionic form to provide a strong Fe–O(alkoxide) bond,
plus an intramolecular hydrogen bond between the drug’s
Fig. 1 DFT-optimized structures of mononuclear FePPIXH–drug complexes. Atom colours are as follows; FePPIXH carbon, light grey; drug carbon,
dark grey; hydrogen, white; chlorine, light green; ﬂuorine, cyan; iron, dark green; nitrogen, blue; oxygen, red. Hydrogen atoms attached to carbon
are omitted for clarity.
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NH+ moiety and the –CO2
− group of FePPIXH. In principle,
these drugs could form the intramolecular hydrogen bond
with either of the propionate groups of FePPIXH, depending
on the conformations of the complexes. We designate the con-
formations observed in the crystal structures as QN(1) and
QD(1). Alternative conformations, allowing the drugs to switch
to the other propionate, have also been modelled by DFT cal-
culations and are designated as QN(2) and QD(2) respectively;
pictures of all four structures are given in Fig. 1. These
conformers proved to be slightly higher in energy, by 1.9 and
2.6 kcal mol−1 respectively in n-octanol, compared to the crystal
structure conformers. This is expected, since these confor-
mations were not observed by crystallography; nevertheless, they
are predicted to be energetically accessible in both n-octanol and
water (see Table 2). Their significance is that one of each pair of
complex structures is suitable for binding to the opposing {001}
and {011} faces of the β-haematin crystal, as discussed below.
The crystal structures of both the QN and QD complexes showed
disorder of the vinyl and methyl groups of the FePPIX moieties;
a calculation on the alternative arrangement for the QD(1)
complex gave virtually identical energies, of +0.3 and +0.1 kcal
mol−1 in n-octanol and water respectively; this is within the error
margin of our calculations. Hence, this type of isomerism has
not been investigated further for any drugs.
Next, we spliced each of these four models within the
β-haematin unit cell, to investigate their ability to coat the
crystal faces. The usual trend was observed, such that steric
hindrance prevented stacking along the c-axis only, but both
the {001} and {011} faces could be coated by a monolayer of
the complementary drug complex. Specifically, conformers
QN(2) and QD(1) can form cyclic propionic acid hydrogen
bonds with the (001) face, whilst QN(1) and QD(2) are suitable
for the (001ˉ) face. The coverage of opposing {001} faces by the
two QN complexes is illustrated in Fig. 3. The SSA analysis,
Fig. 2, showed that these mononuclear complexes of QN and
QD are typical in terms of their crystal surface coverage.
Recent AFM experiments have shown that CQ (or an
FePPIX–CQ complex) absorbs on {100} terraces of growing
β-haematin crystals, poisoning the growth of new layers on
these crystal faces.7,8 We decided to investigate this possibility
for our FePPIXH–QD complex, as representative of the 1 : 1
complexes described in this work. In terms of crystal model-
ling, this presents a more complicated problem than the con-
struction of monolayers on crystal surfaces, since a growing
island presents many diﬀerent environments for the attach-
ment of inhibitors, rather than just one. Our approach was to
construct an 8 × 10 unit cell model of the β-haematin (100)
face, with an irregular island of 14 (FePPIXH)2 dimers on its
Table 2 Calculated method 3 energies for formation of 1 : 1 complexes of zwitterionic antimalarial drugs with FePPIXH in n-octanol (values for
water are given in parentheses), together with Fe–O(drug) bond lengthsa
ΔE (step A1)/kcal mol−1 ΔE (step A2)/kcal mol−1 ΔE (A1 + A2)/kcal mol−1 Fe–O bond length/Å
1. Secondary alcohols
MQ +20.3 (+14.0) −34.3 (−20.8) −14.0 (−6.8) 1.873 (1.892, 1.899)
HN +26.3 (+19.2) −32.2 (−19.8) −5.8 (−0.5) 1.865 (1.840)
LM +22.4 (+16.4) −28.8 (−17.9) −6.4 (−1.4) 1.876
QN(1) +18.6 (+13.8) −31.5 (−18.9) −12.9 (−5.1) 1.866 (1.866)
QN(2) +18.6 (+13.8) −29.6 (−16.9) −11.0 (−3.1) 1.866
QD(1) +18.5 (+13.4) −31.8 (−19.5) −13.3 (−6.1) 1.874 (1.862)
QD(2) +18.5 (+13.4) −29.1 (−16.9) −10.7 (−3.5) 1.869
2. Phenols
AQ +11.0 (+7.5) −17.3 (−8.0) −6.3 (−0.4) 1.885
DAQ N/Ab N/A −10.3 (−3.7) 1.883
TQ +14.0 (+10.8) −17.9 (−10.1) −3.9 (+0.7) 1.927
a Experimental bond lengths are given in parentheses (see main text for references). b All 30 DFT calculations on zwitterionic conformers of DAQ
reverted to the neutral form upon geometry optimization.
Fig. 2 Calculated single and plug shared surface areas (SSA’s) for
FePPIXH–drug complexes. Black diamonds are values for the native
(FePPIXH)2 dimer; the dotted line linking these points is included as a
visual aid. Circles and squares are points for the {001} and {011} faces
respectively. Points inside and outside of the dashed circle are for the
mononuclear complexes of zwitterionic drugs and the dinuclear μ-oxo
complexes respectively. The data points for [(FePPIXH)2(μ-O)(PQH2)] are
labelled ‘PQ’. Other points are coloured as follows; QN, cyan; QD, dark
blue; MQ, red; HN, orange; LM, grey; AQ, light green; DAQ, dark green;
TQ, pink; CQ, yellow; MP, black.
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surface. It proved possible to surround this island with 12
FePPIXH–QD complexes, each of which is in a unique environ-
ment (Fig. 4). In all cases, the drug complexes were able to
form the propionate hydrogen bond with the base layer of the
crystal; in order to do this, the QD(1) isomer was required for
nine of the positions, and the QD(2) isomer for the remaining
three (see Fig. 4 caption). The resulting poisoned island model
was analysed for SSA values in a similar way to the surface
monolayer models; plug SSA’s were measured by deleting each
individual QD complex in turn from the complete model, and
single SSA’s were measured for each individual QD complex
attached to the β-haematin surface plus island model. For
comparison, a further model was constructed in which the QD
complex molecules were replaced by (FePPIXH)2 dimers, repre-
senting the normal growth of the island in the absence of the
drug. The results of these SSA calculations are shown in Fig. 5.
The dotted line represents the situation where the plug and
surface SSA values are identical, which will be the case when
Fig. 3 MM-optimized models of the {001} and {011} β-haematin crystal faces coated by a monolayer of the FePPIXH–drug complex. The base
β-haematin crystal is coloured blue. The central drug complex molecule is rendered in atomic colours (see Fig. 1 caption), and the surrounding drug
complexes are coloured yellow.
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there is no synergy between a bound molecule and its neigh-
bours in the growing layer; all data points must lie on or
above this line. We find that the overall range of single SSA’s
for the QD complexes lies within that of the (FePPIXH)2
dimers, suggesting that FePPIXH–drug molecules can
compete with native (FePPIXH)2 dimers for individual island
growth sites. Since all of the data points for the drug com-
plexes lie very close to the limit where the surface and plug
SSA’s are equal, there is very little synergy between adjacent
complex molecules; this is also evident from Fig. 4, where
each drug complex is essentially independent of its neigh-
bours. Overall, our results suggest that as well as coating the
{001} and {011} faces, these 1 : 1 FePPIX–drug complexes can
also hinder the growth of steps and/or islands on other
crystal surfaces such as the {100} faces. Given the consider-
able variations in SSA’s shown in Fig. 5, poisoning of these
growth sites is likely to be anisotropic, with some binding
sites preferred over others.
To the best of our knowledge, there is no experimental evi-
dence for a 2 : 1 FePPIX–drug complex of either QN or QD.
However, since these drugs incorporate a quinoline moiety, we
decided to investigate whether they can stabilise their corres-
ponding oxo-bridged dinuclear complexes, analogous to the
known complex of CQ (see Introduction). To our surprise, our
DFT calculations yielded viable geometries for both
[(FePPIXH)2(μ-O)(QNH2)] and [(FePPIXH)2(μ-O)(QDH2)], as
shown in Fig. 6. In common with the equivalent CQ complex,
the drug molecules are protonated at both the quinoline and
amino nitrogen atoms, allowing hydrogen bonds with both the
central oxo ligand and the FePPIX propionate group; these
complexes should also benefit from very similar π–π stacking
interactions. In addition, both the QNH2
2+ and QDH2
2+ moi-
Fig. 4 Stereo views of island blocking by the mononuclear QD complex and the dinuclear CQ complex on the (100) face of β-haematin. The base
β-haematin crystal is coloured blue. The surface island, composed of 14 (FePPIXH)2 dimers, is shown in orange. The drug complexes are rendered in
atomic colours (see Fig. 1 caption). In both cases, the three drug complex molecules on the bottom right diagonal are of the alternate conformation,
in order to match the propionate hydrogen bonding pattern of the base layer.
Fig. 5 Single and plug SSA values for molecules surrounding an island
of 14 (FePPIXH)2 dimers on the (100) face of β-haematin. Black diamonds
are for native (FePPIXH)2 dimers, blue circles for mononuclear [FePPIXH
(QD)] complexes, and yellow circles for dinuclear [(FePPIXH)2(μ-O)
(CQH2)] complexes. The dotted line represents the case where plug
SSA = single SSA.
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eties use their alcohol groups to form an additional hydrogen
bond to a second FePPIX propionate group, which has no par-
allel for the CQ complex.
For purposes of comparison, we can define equations for
the formation of these 2 : 1 complexes in two diﬀerent ways,
C1 and C2 (Scheme 3). The calculated energies for these reac-
tions are given in Table 3, along with the calculated Fe–O
bond lengths and asymmetric ν(Fe–O–Fe) frequencies. Except
for CQ, all the 2 : 1 complexes considered in this work were too
large to obtain method 3 energies; therefore, these values were
calculated with method 1. The formation energies for the 2 : 1
complexes of QN and QD are very similar to those for the
experimentally observed CQ analogue (see below). Hence, our
DFT calculations imply that QN and QD can form either 1 : 1
or 2 : 1 complexes with FePPPIX, depending on the relative
concentrations of the reactants, together with the availability
of water for provision of the bridging oxo ligand in the latter.
As with the 1 : 1 complexes, the 2 : 1 complexes of QN and QD
will match only one of each pair of crystal faces; therefore, for
QD, we have also modelled a second conformation in which
the alternative propionate is available for docking with the
crystal surface (the matching surfaces are given in the foot-
notes to Table 3). This alternative conformation is only
0.8 kcal mol−1 higher in energy (in n-octanol). Our surface ana-
lyses indicate that these 2 : 1 complexes give better surface cov-
erage of both the {001} and {011} faces than the corresponding
1 : 1 complexes, particularly with respect to the plug SSA values
(Fig. 2). This can be ascribed to both to the larger sizes of the
dinuclear complexes, and to partial occupation of the crystal
surface corrugations by the quinuclidine vinyl group for the
latter.
To summarize this section; we predict that both QN and
QD can form either 1 : 1 or 2 : 1 complexes with FePPIX,
depending on relative concentrations and the availability of
Fig. 6 DFT-optimized structures of the dinuclear, μ-oxo bridged FePPIXH–drug complexes. Atom colours as in Fig. 1. Hydrogen atoms attached to
carbon are omitted for clarity.
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water. The former have been observed by X-ray crystallography,
whilst the latter are currently unobserved to the best of our
knowledge, but are predicted to be the more stable form by
our calculations (cf. Table 3 energies for step C2 in Scheme 3),
and also give better crystal surface coverage.
Chloroquine, mepacrine and piperaquine
X-ray crystal structures of free CQ36 and PQ37 are available. Our
calculated minima for CQ in n-octanol and water were slightly
diﬀerent, due to rotation of the –N(Et)2 group, with very small
associated energy diﬀerences (<0.2 kcal mol−1). The X-ray
structure of CQ diﬀered from both, in that the CCCN torsion
for the –N(Et)2 group was −73.9° rather than values of ∼180°
for the two model structures; since the all-trans arrangement
should be preferred for an isolated molecule, this discrepancy
can be attributed to compacting of the molecule in the crystal
structure. Similarly, the single global minimum for PQ in both
solvents had an all-trans conformation for the central –N
(CH2)3N– moiety, compared to a gauche/trans arrangement in
the X-ray structure. For both CQ and PQ, geometry optimi-
zations of the X-ray crystal structures indicated that they were
ca. 0.7 kcal mol−1 higher in energy than the calculated global
minima, in n-octanol as solvent.
Since CQ, MP and PQ lack any hydroxy functional groups,
they cannot form an alkoxide complex. Furthermore, DFT cal-
culations indicate that the three nitrogen atoms of CQ should
all bind rather weakly to the iron(III) centre of FePPIX.22 We
have previously postulated a 1 : 1 complex of CQ, formulated as
[FePPIXH(OH)(CQH)], in which the drug stabilizes a hydroxyl
ligand on the Fe(III) centre (Fig. 1).28 Formation of this 1 : 1
complex is predicted to be energetically neutral in water, but
favourable in n-octanol (see Table 4; as usual, these values do
not include the π–π stacking contribution, which is expected to
be ∼3.9 kcal mol−1 for the quinoline group in water,30 and
rather less in n-octanol31). This 1 : 1 complex is currently
unknown from experiment; however a related 2 : 1, oxo bridged
complex has recently been experimentally characterized in
solution.20 Our DFT model of the 2 : 1 complex
[(FePPIXH)2(μ-O)(CQH2)] is shown in Fig. 6; its direct for-
mation is represented by reaction C1 in Scheme 3. Based on
our method 3 DFT calculations, the energetics of this reaction
are remarkably similar to those of the 1 : 1 complex, being
neutral in water but favourable in n-octanol (Tables 3 and 4).
Hence, π–π stacking is probably decisive in stabilizing the 2 : 1
complex over the 1 : 1 complex, since this interaction should
be greater for the former compared to the latter. The calcu-
lated Fe–O bond lengths for [(FePPIXH)2(μ-O)(CQH2)] are in
good agreement with experiment (Table 3); the calculated
asymmetric ν(Fe–O–Fe) stretching frequency of 678 cm−1 is
rather lower than the experimental value of 744 cm−1, but this
is perhaps unsurprising given the complexity of this
vibrational mode. For comparison, the experimental IR spec-
trum of the drug-free oxo complex shows the ν(Fe–O–Fe)
stretch at 880 cm−1, whilst DFT calculations on the
[(FePPIX)2(μ-O)]4− ion using the OPBE functional and LanL2DZ
basis set underestimated this frequency also, placing it at
724 cm−1.38 Meanwhile, a trial calculation on the drug-free
Table 3 Calculated method 1 energies for formation of 2 : 1 complexes of antimalarial drugs with Fe(PPIXH) in n-octanol (see Scheme 3; values for
water are given in parentheses), together with Fe–O bond lengths and ν(Fe–O–Fe) frequenciesa
ΔE (reaction C1)/kcal mol−1 ΔE (reaction C2/C3)/kcal mol−1 Fe–O /Å ν(Fe–O–Fe)/cm−1
1. Drugs lacking –OH groups
[(FePPIXH)2(μ-O)(CQH2)] −32.6 (−23.4) −11.4 (−10.3) 1.849, 1.865 (1.87)b 678 (744)b
−8.5 (0.0)c −1.0 (0.0)
[(FePPIXH)2(μ-O)(MPH2)] −26.1 (−15.2) −4.0 (−1.6) 1.851, 1.865 672
[(FePPIXH)2(μ-O)(PQH2)] −10.2 (−0.2) +12.2 (+11.9) 1.846, 1.862 685
2. Secondary alcohols
[(FePPIXH)2(μ-O)(QNH2)]d −32.8 (−21.2) −10.8 (−7.3) 1.856, 1.873 661
[(FePPIXH)2(μ-O)(QDH2)]e −32.1 (−20.7) −9.5 (−5.7) 1.857, 1.873 659
[(FePPIXH)2(μ-O)(QDH2)]d −31.4 (−19.6) −8.7 (−4.6) 1.863, 1.864 661
3. Phenols
[(FePPIXH)2(μ-O)(AQH2)] −17.4 (−7.1) −6.0 (−3.6) 1.849, 1.861 683
[(FePPIXH)2(μ-O)(DAQH2)] −25.0 (−12.7) −11.7 (−7.4) 1.846, 1.860 684
[(FePPIXH)2(μ-O)(TQH2)] −23.5 (−12.3) −11.5 (−7.7) 1.848, 1.861 682
a IR frequencies are uncorrected. b Experimental values taken from ref. 20. c Values for [(FePPIXH)2(μ-O)(CQH2)] shown in italics were obtained by
method 3; the other complexes were too large for this method. d Isomer suitable for binding to the (001) crystal face of β-haematin. e Isomer suit-
able for binding to the (001ˉ) crystal face.
Table 4 Calculated method 3 energies for formation of 1 : 1 hydroxide
complexes of antimalarial drugs with Fe(PPIXH) in n-octanol (see step
B1 in Scheme 3; values for water are given in parentheses), together
with Fe–O bond lengths
ΔE (step B1)/kcal mol−1 Fe–O bond length/Å π–π stackinga
1. Drugs lacking –OH groups
CQ −7.5 (0.0) 1.836 Yes
MP −8.4 (−0.5) 1.824 Marginal
PQ −4.4 (+5.4) 1.788 Marginal
2. Phenols
AQ −1.0 (+6.2) 1.908 Yes
DAQ −4.3 (+2.7) 1.894 No
TQ −4.1 (+2.6) 1.893 No
a Visual assessment of whether the geometry of the complex is suitable
for π–π stacking between the drug’s aromatic rings and the porphyrin.
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hydroxyl complex [(FePPIXH)(FePPIXH2)(μ-OH)] gave a much
lower ν(Fe–O–Fe) frequency of 506 cm−1 (note that for all of the
2 : 1 complexes in Table 3, the calculated geometries indicate a
central oxo ligand supported by a hydrogen bond from the
drug’s protonated aromatic N, rather than proton transfer
from the drug to give a bridging μ-OH ligand, such that the
N–H and NH⋯O distances are 1.04–1.06 and 1.71–1.93 Å
respectively).
Overall, our calculations are consistent with the 2 : 1
complex of CQ being the preferred product, especially in view
of the higher concentration of FePPIX compared to CQ under
biological conditions; however, we cannot rule out a kinetic
role for the 1 : 1 complex, either in the dynamic process of
crystal growth poisoning, or as an intermediate in assembly of
the 2 : 1 complex (reaction C3 in Scheme 3). Indeed, we found
that shifting a proton from the free propionic acid group of
the 1 : 1 complex to the quinoline nitrogen gave a tautomer,
formulated as [FePPIX(OH)(CQH2)], that was not much higher
in energy (+3.9 and +3.5 kcal mol−1 in n-octanol and water
respectively), as shown in Fig. 1. This structure can be
described as intermediate between the 1 : 1 and 1 : 2 com-
plexes. It finds experimental precedent in the X-ray crystal
structure of a 2 : 2 gallium(III) protoporphyrin IX complex of
CQ, formulated by Dodd and Bohle as [GaPPIX(OMe)(CQ)]2, in
which the protonated quinoline of the CQH2
2+ moiety is hydro-
gen bonded to the methoxide O atom, whilst the protonated
amine group is hydrogen bonded to propionate.39
Turning to mepacrine, we were able to model a 1 : 1 hydroxyl
complex of formula [(FePPIXH)(OH)(MPH)], whose energy of
formation is similar to that of the analogous CQ complex
(Table 4). Similarly, the 2 : 1 complex [(FePPIXH)2(μ-O)(MPH2)]
was also modelled (Fig. 6). The energy of formation of the
latter, using method 1 (Table 3), though somewhat less favour-
able than for the CQ analogue, suggests that this species
would be accessible in solution. Overall, we infer that like CQ,
either or both of the 1 : 1 and 2 : 1 complexes of MP could be
present under the conditions within the parasite’s DV. Similar
results were obtained for piperaquine, although the 1 : 1 and
the 2 : 1 complexes are both predicted to be less stable than
their CQ and MP analogues (Tables 3 and 4). The large size of
PQ limited the number of complex geometries that could be
investigated, possibly biasing our results; the structures of the
1 : 1 and 2 : 1 complexes are given in the ESI† and Fig. 6
respectively. Although our method 1 calculations suggest that
the 1 : 1 complex is more stable than the 2 : 1 complex in this
case, we note that the geometry of the 1 : 1 complex is poorly
suited for π–π interactions between the quinoline and haem
rings, whereas the 2 : 1 complex should benefit from such
interactions, since the quinoline ring is intercalated between
the two haem rings. Hence, the two complexes should be more
similar in energy than predicted by our DFT calculations.
In terms of their ability to poison the growth of β-haematin,
the SSA’s of the 1 : 1 complexes of CQ, MP and PQ on the {001}
and {011} crystal faces were all in the typical ranges (see ESI,
section 14†). However, all three 2 : 1 complexes gave signifi-
cantly better surface coverage (Fig. 2). In particular, the pipera-
quine 2 : 1 complex gave the best surface coverage of all the
drugs considered in this work. This can be attributed to the
extra quinoline group of PQ, which fits very well within the cor-
rugations of these crystal faces. It should be noted that CQ
and MP are both used as mixtures of the two possible stereoi-
somers, whilst PQ lacks any stereocentres; hence the question
of stereochemical matching between the drug complexes and
opposing crystal surfaces does not require detailed analysis for
these drugs.
In view of recent AFM observations of poisoning of the
{100} terraces of β-haematin by CQ,7,8 we investigated the
ability of the 2 : 1 FePPIX–CQ complex to surround our model
of an island on the (100) crystal face, as described above for
the 1 : 1 QD complex (Fig. 4). Similar results were obtained;
thus, 12 molecules of [(FePPIXH)2(μ-O)(CQH2)] were used to
surround the island; as before, three of these required the
alternative conformation in which the other propionate group
is available for hydrogen bonding to the crystal surface (since
CQ is used as a mixture of stereoisomers, this was generated
by simply reflecting the original model). As shown in Fig. 5,
the surface SSA’s for the 2 : 1 CQ complex again fitted within
the range of values for the native (FePPIXH)2 dimer, and
tended to be superior to the values for the smaller 1 : 1 QD
complex. Furthermore, some of the plug SSA values suggest a
degree of synergy for adjacent binding of 2 : 1 complex mole-
cules. Since these results are in qualitative agreement with the
crystal surface coverage properties shown in Fig. 2, we con-
clude that in general, the 2 : 1 complexes give better surface
coverage than the 1 : 1 complexes, both in providing a mono-
layer on the {001} and {011} faces, and in blocking terrace or
island growth on other faces.
Amodiaquine and tebuquine
The X-ray crystal structure of AQ propanol solvate is avail-
able.40 Our calculated minimum, which was the same in both
n-octanol and water, diﬀered only in alternative arrangements
of the ethyl groups of the –NEt2 moiety; optimization of the
crystal structure showed it to be <0.3 kcal mol−1 higher in
energy in both solvents, hence this diﬀerence can be attributed
to crystal packing eﬀects. Both the calculated and experimental
structures show an intramolecular hydrogen bond between the
phenol –OH and the tertiary amine; a feature that is also
present in our calculated structure of TQ. AQ and TQ are repre-
sentatives of a family of drugs that incorporate phenolic
groups, in addition to quinoline and amine functionalities.
Hence, these drugs might act in a similar way to CQ, recruiting
water to form either a 1 : 1 or a 2 : 1 complex with FePPIX; or
alternatively they might form a direct Fe–O bond via phenol-
ate. Since AQ is rapidly hydrolysed to desethyl amodiaquine
(DAQ) in vivo,41 we have also included the latter in our calcu-
lations. The calculated energies for formation of the three
diﬀerent complexes of each drug are given in Tables 2–4, and
the structures of the zwitterionic and dinuclear complexes are
shown in Fig. 1 and 6 respectively. The higher acidities of
phenols should make zwitterion formation easier than for the
alcohols, and this is confirmed by the lower step A1 energies
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for these drugs (Table 2); however, the Fe–O bonds (step A2)
are proportionately weaker, such that the overall formation
energies for the phenoxide complexes are very similar to those
of the alkoxides.
DAQ always gives superior complexation energies than AQ,
hence the rapid metabolism of AQ to DAQ should enhance the
biological eﬀect of this drug. For all three drugs, the two
alternative 1 : 1 complexes involving phenoxide or hydroxide
Fe–O bonds have favourable energies of formation in n-octanol
(Tables 2 and 4 respectively); however these 1 : 1 complexes
tend to have geometries that are poorly suited to π–π stacking
of the quinoline with the porphyrin (Fig. 1 and Table 4). Also,
the extra chlorophenyl group of TQ introduces steric bulk
which destabilizes the phenoxide complex, reflected in a
longer Fe–O bond length and weaker energy of formation com-
pared to the AQ and DAQ complexes (Table 2). Comparison of
the method 1 energies for formation of the 2 : 1 complexes
with that for CQ (Table 3) suggests that these species should
also be accessible, and will benefit from similar π–π stacking
interactions (see Fig. 6). The chlorophenyl substituent of TQ
does not perturb the structure of the 2 : 1 complex. Similar to
the dinuclear complexes of QN and QD, the hydroxy groups of
DAQ and TQ are involved in hydrogen bonding to the propio-
nate groups of FePPIXH.
In terms of β-haematin surface coverage, these drugs give
typical results (Fig. 2); both forms of the 1 : 1 complexes give
single and plug SSA values in the usual ranges for the {001}
and {011} crystal faces, whilst the 2 : 1 complexes give superior
SSA values. Overall, our results suggest that the 2 : 1 complexes
of DAQ and TQ are most likely to be the active forms of AQ
and TQ respectively, in which case the main function of the
phenol group is to provide an additional hydrogen bond to
propionate within these complexes.
Conclusion
The ten antimalarial drugs considered in this work are all
known to interfere with the growth of β-haematin crystals, but
the precise molecular basis of this interaction is currently
unknown from experiment. In particular, the question of
whether the drugs adhere directly to the crystal surface, or
whether they act by forming molecular complexes with FePPIX,
remains unresolved. We do know from experiment that QN,
QD, HN, and MQ all form 1 : 1 complexes with FePPIX, whilst
CQ forms a 2 : 1 complex. In this work, we have shown that all
ten drugs can form at least one type of complex with FePPIX,
with geometries and energies that are comparable to the
experimentally established cases. Our results are summarized
in the Venn diagram in Scheme 3. Only three of the drugs,
namely HN, MQ, and LM, are limited to 1 : 1 complexes with
FePPIX, being unsuitable for the formation of a 2 : 1 μ-oxo
complex (C). Since the 1 : 1 zwitterionic complexes (A) of HN
and MQ have been experimentally characterized, we have not
considered the alternative 1 : 1 hydroxide complexes (B) in this
work; we note, however, that recently published DFT calcu-
lations on such a complex for MQ33 suggest that this may be
another possibility. On the other hand, CQ, MP, and PQ all
lack hydroxy groups and so require water to form either
1 : 1 hydroxide (B) or 2 : 1 μ-oxo (C) complexes, whilst QN and
QD can either recruit water to form a 2 : 1 μ-oxo complex, or
react directly with FePPIX in their zwitterionic forms. TQ, AQ
and DAQ are the most versatile of all; each can form three dis-
tinct complexes with FePPIX, at least in silico. The five drugs
for which we have modelled 1 : 1 hydroxide complexes can also
give 2 : 1 μ-oxo complexes, and furthermore the 2 : 1 complexes
give better crystal surface coverage. Together with the lack of
any experimental evidence for their existence, we suspect that
the 1 : 1 hydroxide complexes are probably the least important
in terms of crystal poisoning, although they may serve as inter-
mediates in formation of the 2 : 1 μ-oxo complexes. The ability
to complex with FePPIX in more than one way might be a
useful property for these drugs, since it could help to keep the
drug associated with FePPIX under conditions of diﬀerent con-
centrations of the drug, FePPIX and water, as well as pH and
solvent polarity. From an experimental point of view, our
results reaﬃrm the caveat that observation of any particular
complex under a given set of in silico or even in vitro conditions
should not be over-interpreted to exclude other possibilities
which could be more relevant in vivo. Indeed, although both
MQ and LM have been shown to inhibit the growth of
β-haematin in vitro, recent experiments suggest that they have
little or no eﬀect on the development of haemozoin crystals in
living parasites.42
Crystal growth poisoning is facilitated if a drug or its
complex can recognise a variety of diﬀerent crystal surfaces,
including faces, steps and islands. This is probably the stron-
gest indicator that their complexes with FePPIX are the func-
tionally relevant forms of these drugs. Nothing resembles the
native (FePPIXH)2 dimer more closely than an FePPIX–drug
complex. Each of these drug complexes has a free propionic
acid group, which can form the hydrogen bonding dimer that
is the only polar interaction on the crystal surfaces. Recurring
structural motifs among these drugs (quinoline groups,
amines, alcohols, and their geometric relationships) can all be
rationalized in terms of the structures of their corresponding
complexes with FePPIXH. According to our surface coverage
models, a common shortcoming of most drugs is that they do
not occupy the deep corrugations on the {001} crystal faces.
For example, lumefantrine has the highest surface area among
the free drugs, but the {001} face corrugations remain unoccu-
pied by the [(FePPIXH)(LM)] complex, with the aromatic group
projecting away from the surface (see sections 13 and 16 of the
ESI†). The exception is the 2 : 1 complex of PQ, in which one of
the two chloroquinoline groups is located within the corruga-
tion, although this complex is predicted to be less stable than
the other 2 : 1 complexes. This suggests a promising avenue
for future drug design; to search for drugs that form stable
1 : 1 and/or 2 : 1 complexes with FePPIX, and also possess sub-
stituents that can occupy the β-haematin surface corrugations.
Our own eﬀorts in this regard have focussed on 1 : 1 complexes
in which the zwitterionic form of the drug is more accessible
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than for known drugs; the results of these studies will be pub-
lished in due course.
Finally, it should be remembered that poisoning haemo-
zoin crystal growth is not, of itself, the final goal of such
drugs. Rather, it is to increase the concentration of reactive
FePPIX species in solution to levels that are toxic to the para-
site. A five-coordinate alkoxide or μ-oxo FePPIX–drug complex,
whilst desirable for crystal poisoning, is probably less toxic
than free FePPIX to the parasite, since the iron centre(s)
should be more inert than those of the free haem. Hence,
these drugs must poison haemozoin formation in a concen-
tration regime that is well below that of FePPIX in the digestive
vacuole, as is indeed the case.7
Computational methods
DFT and MM calculations were performed with
Gaussian09 43 ¶ and Accelrys Discovery Studio44 respectively.
Input geometries for both DFT and MM calculations were
created using Hyperchem 8.0.10.45 Gaussian input and output
files were processed with MolDraw 2.0 46 and GaussView 5.0.
Figures of molecular structures were prepared using Ortep-3
for Windows.47 Conformations of the free drugs as inputs for
DFT calculations were generated with Hyperchem, using the
conformational searching facility on all rotatable bonds to
locate sets of distinct, low energy conformations. Additional
conformations were located with short (10–100 ps), high tem-
perature (300–800 K) molecular dynamics runs, followed by
MM geometry optimization.
The standard procedure for DFT calculations on the iron
complexes using method 3 was as follows. An initial gas phase
calculation and wavefunction stability check at the B3LYP/
LanL2DZ level of theory was followed by geometry optimiz-
ation and frequency calculations, also at the B3LYP/LanL2DZ
level, and finally single point implicit solvent calculations at
the optimized geometry using B3LYP/6-311+G(d,p) with SMD
solvent corrections and additional wavefunction stability
checks (the corresponding method 1 results, using B3LYP/
LanL2DZ for the solvent calculations also, are given in the
ESI†). Quadratic convergence (QC) was used sparingly, to assist
convergence for particularly troublesome structures. Often, it
proved more eﬃcient to avoid QC and instead run a series of
final single point calculations in which the basis set was suc-
cessively incremented from 6-31G to 6-311+G(d,p). The ground
spin state for the 1:1, 5-coordinate Fe–O haem complexes was
taken as S = 5/2, as determined in our previous DFT studies22
and also observed experimentally for the 1 : 1 complex of QN.48
Initial calculations on [(FePPIXH)2(μ-O)(CQH2)] showed that
the antiferromagnetically coupled, S = (±5/2 = 0) species is
more stable than the ferromagnetically coupled S = 10/2 state
by ca. 5 kcal mol−1 in both n-octanol and water, in agreement
with NMR measurements that showed this species to be anti-
ferromagnetically coupled.48 All subsequent calculations on
the 2 : 1 complexes were carried out with antiferromagnetic
coupling (see Methodology section). All reported reaction ener-
gies have been corrected for zero-point energies (ZPE’s), which
were scaled by a factor of 0.981.22
Models of the crystal surfaces with drug complex mono-
layers were assembled by rigid body modelling in Hyperchem,
using the native β-haematin unit cell as a template (see
Methods section). These were then converted into mdl format
files, suitable for Discovery Studio, with OpenBabel.49 Models
of the (100) face islands surrounded by drug complex mole-
cules were created within Discovery Studio, by substituting
(FePPIX)2 dimers in a pure β-haematin model with the
required complex, using the heavy atoms of the hydrogen-
bonded propionic acid group as a template. Subsequent geo-
metry optimizations of both types of poisoned crystal models
were carried out within Discovery Studio, using the CHARMm
force field and adopted basis Newton–Raphson algorithm to
an RMS gradient of 0.1 kcal mol−1 Å−1; other parameters were
left at their default values. Surface areas for SSA calculations
were measured using a 1.4 Å solvent probe; first, the surface
area of the complete model was measured; then, the areas of
two sub-components (one complex molecule plus the rest of
the model); the diﬀerence between the complete model and
the sum of its two components was divided by two to obtain
the SSA.
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